Georgia Bio Names South Forsyth High School Junior as 2022 Georgia BioGENEius Winner

Mokshith Mannuru Advances to International Competition Against Top Students

Georgia Bio and the BioEd Institute named  Mokshith Mannuru , a junior at South Forsyth High School in Cumming, GA, as the winner of the 2022 Georgia BioGENEius Challenge. The BioGENEius Challenge is the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. As Georgia’s BioGENEius finalist, Mokshith will attend the 2022 International BioGENEius competition, which will be held during the 2022 BIO International Convention, the industry’s trade conference from June 13-16 in San Diego, CA. There he will engage with leading companies, scientists and innovators currently transforming the scientific landscape and gain valuable insights into an industry making significant contributions to the world.

While in San Diego, Mokshith will compete against high school students from the U.S., Canada, and Germany in the International BioGENEius Challenge. The student projects will represent a range of biotechnology topics such as healthcare, agriculture, and the environment.

Mokshith’s project uses bioinformatics to identify the common function of genes that are related to Autism Spectrum Disorder (ASD). Over 1,000 genes are evidenced to contribute to ASD but are not understood well enough to use genetics in diagnosing or treating ASD. Mokshith hypothesized that these genes contribute to human development and would therefore affect development if a copy of the gene were faulty. He used data from the International Mouse Phenotyping Consortium (IMPC) to observe the phenotypes of mice where the ASD genes that are also found in mice were knocked out (deleted). The missing genes were found to strongly affect development or behavior, or lead to embryonic lethality. ASD patients would have one mutated copy of a gene related to ASD and one normal copy. This research suggests several pathways and development processes that attribute to ASD and could be used to validate ASD mouse models that are used in biomedical research.

“The level of competition in Georgia was at an all-time high this year,” said Georgia Bio President and CEO Maria Thacker. “Georgia Bio is thrilled to have Mokshith represent our state on the international stage at the upcoming BIO Convention, and we are proud to support this Georgia scholar in his future endeavors.”

Georgia Bio also congratulates the Georgia BioGENEius runner-up,  Varun Sendilraj ,who is a senior at Lambert High School in Suwanee, GA. Varun developed a mobile app, DFUCare, which uses deep-learning algorithms to diagnose, analyze and monitor Diabetic Foot Ulcers (DFU) in diabetes patients. DFU is a major complication of diabetes mellitus that can lead to amputation and mortality if left untreated. Caring for DFU can be expensive and time consuming, which limits treatment options for many patients around the globe. DFUCare quantifies the size of wounds, performs tissue analysis, and detects healing potential over time. It can also allow doctors and patients to share medical reports with experts, saving time and resources for treating diabetic foot ulcers.

Judging the 2022 Georgia BioGENEius Challenge were Jamie L. Graham, Boehringer Ingelheim; Ralph L. Cordell, CDC; Ian Biggs, UGA; and Alex Harvey, ViaMune, Inc.

“I am amazed at the quality and thoughtfulness of the projects on display,” said Ian Biggs of UGA’s Innovation Gateway. “The insights displayed, and the obvious effort put into the projects is way beyond my expectations.”

National and International winners will be announced after the competition. See the  International BioGENEius website  for more information on the 2022 schedule. Winners will receive cash scholarships.

Follow the BioGENEius Challenge:  Throughout the challenge, @BiotechInstitut will be tweeting interviews, photos, and engaging with the biotechnology community by using the hashtag #BioGENEius.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the BioEd Institute

The BioEd Institute, a division of the 501(c)(3) nonprofit the Center for Global Health Innovation, works to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. BioEd works closely with its sister organization Georgia Bio, which serves the state’s life science industry. For more information about BioEd, visit them online at  www.georgiabioed.org , or on Facebook (@GeorgiaBioEd), Twitter (@georgiabioed), or LinkedIn (@georgia-bioed).

Contacts

Kristin Boscan
585.943.8699
kboscan@cghi.org

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS